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Multiple myeloma (MM) is a plasma cell malignancy associated with high levels of monoclonal (M) protein in the blood
and/or serum. MM can occur de novo or evolve from benign monoclonal gammopathy of undetermined significance (MGUS).
Current translational research intoMM focuses on the development of combination therapies directed against molecularly defined
targets and that are aimed at achieving durable clinical responses. MM cells have a unique ability to evade immunosurveillance
through several mechanisms including, among others, expansion of regulatory T cells (Treg), reduced T-cell cytotoxic activity
and responsiveness to IL-2, defects in B-cell immunity, and induction of dendritic cell (DC) dysfunction. Immune defects could
be a major cause of failure of the recent immunotherapy trials in MM. This article summarizes our current knowledge on the
molecular determinants of immune evasion in patients with MM and highlights how these pathways can be targeted to improve
patients’ clinical outcome.
1. Introduction
Multiple myeloma (MM) is a malignant plasma cell (PC)
disorder, accounting for approximately 1% of neoplastic dis-
eases and 13% of all hematological cancers [1]. It may either
present de novo or evolve from amonoclonal gammopathy of
undetermined significance (MGUS) that progresses to smol-
deringmyeloma (SMM) and, finally, to symptomaticMM. In
recent years, the introduction of autologous hematopoietic
stem cell transplantation (HSCT) and the availability of
novel drugs such as thalidomide, lenalidomide, and borte-
zomib, have prolonged overall survival [1]. Patients with
standard risk factors (absence of t(4; 14), t(14; 16), 17p-) are
expected to live for 7 to 10 years from diagnosis, with good
quality of life. In spite of these developments, MM remains
an incurable disease for the vast majority of patients.
MM tumor cells are susceptible to immune recognition,
as suggested by the therapeutic eﬃcacy of allogeneic HSCT in
patients with this disease [2]. In fact, the curative potential
of allogeneic HSCT has been attributed, at least in large
part, to the graft-versus-myeloma eﬀect, at best illustrated by
the induction of sustained molecular remissions after donor
lymphocyte infusions (DLIs) in patients with either relapsed
or persistent disease after allogeneic HSCT [3]. Moreover,
in 357 cases of MM, event-free and overall survival were
improved in patients given autologous-allogeneic HSCT
(tandem transplantation) as compared with patients lack-
ing an HLA-matched sibling donor and receiving double-
autologous HSCT [4]. It should be mentioned that another
study recruiting 710 myeloma patients with both standard-
risk and high-risk disease from 37 transplant centers across
the United States failed to show any superiority of non-
myeloablative (NMA) allogeneic HSCT after autologous
HSCT compared with tandem autologous HSCT in terms of
3-year progression-free and overall survival [5], suggesting
that strategies aimed at enhancing the antimyeloma eﬀect are
needed to improve the outcome of NMA transplants.
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Despite these data indicating that an alloreactive-
mediated, graft-versus-myeloma (GVM) eﬀect may be cru-
cial for tumor eradication, MM is unique in its ability
to elude immunosurveillance, as a result of qualitative
and/or quantitative abnormalities of DC and Treg cells,
and of enhanced release of immunoregulatory cytokines by
microenvironmental cells. Example of the latter mechanism
is secretion, by bone marrow (BM) stromal cells (BMSCs), of
immunomodulatory and proangiogenic growth factors, such
as transforming growth factor (TGF)-β, vascular endothelial
growth factor, interleukin (IL)-6, and hepatocyte growth fac-
tor (HGF). This article will review our current knowledge on
the mechanisms whereby MM cells downregulate/improve
antimyeloma immunity and will discuss how these circuits
can be targeted to improve treatment outcomes.
2. Evidence for an Immune-Mediated
Graft-versus-Myeloma Effect
As previously mentioned, DLI can induce remissions in
patients with either relapsed or persistent MM after allo-
geneic HSCT. Responses to DLI and chronic GVHD are
closely correlated, indicating that cellular/molecular targets
for GVHD andGVM are similar or identical andmay include
the minor histocompatibility antigens (mHa) expressed
on both normal and MM cells of the patients. Limited
chronic GVHD has been correlated with a significantly
decreased risk of myeloma recurrence and with longer event-
free survival after NMA and reduced-intensity conditioning
(RIC) transplants, consistent with a beneficial eﬀect of the
GVM response [6]. The European Group for Blood and
Marrow Transplantation (EBMT) has published the results
obtained in 229 MM patients who received an allogeneic
HSCT with RIC regimens from 33 clinical centres [7].
Chronic GVHD was associated with better overall survival
and progression-free survival that were 84% and 46% for
patients with limited chronic GVHD, 58% and 30% for those
with extensive chronic GVHD, and 29% and 12% in the
absence of chronic GVHD, respectively, again underscoring
the importance of the GVM eﬀect [7].
Support for the role of mHa antigens in the GMV eﬀect
is provided by the experimental observation that malignant
plasma cells may be susceptible to HA1-specific lysis in
vitro [8]. Immune modulating drugs, such as thalidomide,
administered after allogeneic HSCT, might be of therapeutic
interest. Thalidomide, given at low doses and, after an inter-
val of 14 days, followed by DLI, has been reported to improve
responses to DLI, without inducing GVHD [9]. In a series of
18 patients so treated, 2 developed acute GVHD grade I of the
skin, and only 2 developed de novo chronic GVHD. The high
response rate of 67% with 22% complete remission indicated
an additive or synergistic antimyeloma eﬀect.
The cancer testis (CT) antigen class of tumor antigens
is also a potential target for the GVM eﬀect. MAGE-type
genes can be detected in the majority of MM patients with
advanced disease, but not in samples from patients with
MGUS and with stage I/II myeloma [10]. CT10/MAGEC2,
MAGEA3, BAGE, and NY-ESO-1 mRNA have been detected
in about 90% of MM cell lines [11]. MAGEC2 and MAGEC3
were the most frequently expressed CT antigens in a
cohort of 55 patients with advanced MM. Furthermore,
IgG antibodies towards CT antigens were detected in the
serum of 10 out of 66 analyzed samples. Nine out of 10
patients with detectable antibody responses had undergone
allogeneic HSCT. When paired analyses were performed
with sera collected before and after allogeneic HSCT in 7 out
of 9 allotransplanted patients, none of these patients showed
antibody responses against any of the CT antigens in their
pretransplantation sample. The CT antigen NY-ESO-1 also
elicited strong allogeneic T-cell responses in one patient with
MM who received allogeneic HSCT [11]. Through the use
of 12mer peptides overlapping by a single amino acid and
spanning NY-ESO-1 region 51–70, it was shown that the
CD4+ and CD8+ T-cell responses were both directed against
NY-ESO-151−62. When investigating the HLA restriction
patterns of T-cell responses against NY-ESO-151−62, only
HLA-DQ5-expressing EBV-B cell lines were capable of
presenting NY-ESO-151−62 to the CD4+ T cells, whereas the
CD8+ response against the same peptide was restricted by
HLA-B27. The preferential expression of NY-ESO-1 has also
been described in MM patients with cytogenetic abnormal-
ities [12]. In this study, spontaneous antibody responses
to NY-ESO-1 could be demonstrated in 33% of NY-ESO-
1+ MM patients. Furthermore, NY-ESO-1157−165-specific
T cells, accounting for 0.2–0.6% of CD8+ T cells, were
detected in NY-ESO-1+ MM patients with HLA-A∗0201
tetramers.
Altogether, there is strong evidence to support that
immune responses against myeloma are crucial for disease
control. This implies that strategies aimed at counteracting
the myeloma-induced immune dysfunction should be able
to translate into better outcomes.
3. Immune-Suppressive Molecules
Expressed by MM Cells
The outcome of an immune response is dependent on
the multiple signals exchanged by antigen-presenting cells
(APCs) and antigen-specific T cells, and on the provision of
cytokines and membrane-bound costimulatory molecules,
especially those of the B7-CD28 family [13]. The classi-
cal B7-CD28 pathway includes 2 ligands, B7.1/CD80 and
B7.2/CD86 on cell surface of APC and at least 2 receptors,
CD28 and cytotoxic T-lymphocyte antigen 4 (CTLA-4), on
T cells. The interaction between CD80/CD86 ligands on APC
and CD28/CTLA-4 on T cells controls antigen-specific T-cell
proliferation, anergy, and survival. More recently identified
B7-homologs, including B7-H1/programmed death-ligand
1 (PD-L1), B7-DC/PD-L2, B7-H2/inducible costimulator
ligand (ICOSL)/B7h/B7RP-1, are expressed on APC as well
as on cells within nonlymphoid organs. Both PD-L1 and
PD-L2 interact with PD-1, a member of the CD28 family,
whereas ICOSL is known to bind to ICOS. The expression
of CD86 and ICOSL in acute myeloid leukemia has been
correlated with inhibition of antitumor immunity and with
a poor prognosis [14].
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A survey of murine tumor lines has revealed that
myeloma cell lines naturally express PD-L1 [15]. Growth
of myeloma cells in normal syngeneic mice was inhibited
significantly, albeit transiently, by administration of anti-PD-
L1 antibody in vivo and was suppressed completely in the
syngeneic PD-1-deficient mice [15]. The expression of PD-
L1 by MM cell lines may also be associated with reduced
susceptibility to tumor cell lysis by cytotoxic T-lymphocyte
(CTL) clones [16]. Among a series of cytokines tested, IFN-
γ alone was capable of upregulating PD-L1 expression on
patient-derived MM cells, mainly through the MEK/ERK
signalling pathway [16]. PD-L1 was not detected in patients
with MGUS or in healthy controls. Another study showed
that PD-L1 is expressed by a subset of cycling CD34+CD138+
malignant PC [17]. Interestingly, PD-L1 participates in the
induction and maintenance of Treg cells, in synergy with
TGF-β [18]. In a mouse model of oral tolerance induced
by the intragastric administration of chicken ovoalbumin,
both PD-L1 and PD-L2 expressed on mesenteric lymph
node DC contribute to the promotion of Treg diﬀerentiation
[19].
In contrast to PD-L1, ICOSL is expressed by <10% of
MM cases and is induced by TNF-α and/or autologous
BMSCs [20]. MM cell lines and fresh myeloma samples
also express CD86 [20]. When patients were dichotomized
based on CD86 expression levels, all patients assigned to
the CD86high group had lower hemoglobin and platelet
levels, although there were no diﬀerences in overall survival
between groups [20]. ICOSL was detected only in 3 out
of 35 patients examined, who had either chemotherapy-
resistant disease (2 patients) or plasma cell leukemia (1
patient). Interestingly, it was shown that both autologous
BMSC and exogenous TNF-α upregulate CD86 or ICOSL
expression in >50% of patients examined. Both CD86 and
ICOSL molecules enhanced the production of IL-10 by
T cells that were cultured in vitro with MM cells [20].
It is tempting to speculate that T-cell-derived IL-10 may
also aﬀect antimyeloma responses in addition to promoting
malignant plasma cell proliferation.
Malignant plasma cells in MM express syndecan-1
(CD138). However, clonogenic or “cancer stem cells” may
be enriched in a fraction of CD138− cells that express
intranuclear Sry-HMG-box 2 (SOX2), an embryonic stem
cell marker implicated in self-renewal and pluripotency [21].
IgG antibodies to SOX2 of both κ and λ chain specificity
can be detected in patients with MGUS, but not in those
with either SMM or MM. After stimulation with a library
of overlapping 15-mer peptides spanning the entire SOX2
protein, SOX2-specific T cells could be detected in 11
out of 16 MGUS patients and included both CD4+ and
CD8+ T cells. Conversely, SOX2-specific T-cells could not
be detected from MM patients or healthy donors, even after
repeated antigen stimulation rounds. The SOX2-specific T-
cells were of the Th1 phenotype, as they produced IFN-γ
but not IL-4 or IL-10 upon SOX2 challenge [21]. Impor-
tantly, prestimulation of BM mononuclear cells from MGUS
patients with the SOX2 peptide library is translated into the
inhibition of clonogenic growth, suggesting that targeting
SOX2 immunity may restrain tumor expansion. Finally, with
a median followup of 24 months, MGUS patients with anti-
SOX2 T cells had a significantly lower likelihood of disease
progression, with a 2-year progression-free survival rate of
100% versus 30% in MGUS patients lacking anti-SOX2 T
cells [21]. This study thus underlines that the immune system
has the ability to spontaneously recognize antigens in the
preneoplastic stage of human cancer and that the pattern of
antigens targeted by the T cells in preneoplastic lesions may
diﬀer from that in clinical cancer.
CD28 expression may be higher in malignant PC from
patients with MM compared with SMM and healthy controls
[22]. CD28 was mainly observed in patient subgroups with
poor prognosis, as defined by the genetic signature. Impor-
tantly, myeloid DC that accumulate within the BM niche
of patients with MM exert a prosurvival eﬀect on CD28+
malignant PC that is mediated through CD28 interaction
with CD80/CD86 on the DC. CD28-expressing MM cells
induced IL-6 production upon coculture with CD80/CD86-
expressing DC, a phenomenon that was markedly inhibited
by blocking either the CD28-CD80/CD86 or Jagged-Notch-
1 pathways [22]. Finally, the U266 MM cell line enhanced
the IFN-γ-induced expression of IDO in DC, an eﬀect that
was also observed with primary myeloma cells and was
largely CD28-dependent. This study suggests that CD28
expression byMM cells contributes to malignant cell survival
and to the induction of an immune suppressive BM milieu
(Figure 1).
CD200, formerly known as OX-2, is a highly conserved
type I transmembrane glycoprotein that is expressed by
thymocytes, activated T cells, B cells, DC, endothelial cells,
and neurons. CD200 has been detected in malignant PCs of
roughly 80% of patients with newly diagnosed MM [43]. In
a group of 112 newly diagnosed patients treated with HSCT,
patients with CD200neg MM cells had a better event-free
survival (24 months) compared with patients with CD200pos
MM cells (14 months) [43]. When CD200 expression was
tested together with classical prognostic factors (serum albu-
min and serum β2-microglobulin), CD200 expression and
β2-microglobulin remained independent prognostic factors
[43]. The improved event-free survival of patients with MM
cells lacking CD200 could be linked to the role of CD200
in suppression of T-cell-mediated immune responses and in
the development of DC with a capacity to induce Treg cells
[44].
4. Regulatory T-Cells in MM
Conflicting reports have been published on the frequency
of Treg cells in patients with MGUS and MM, with
studies showing either a decrease or an increase of FoxP3-
expressing Treg cells [45–47]. The MM-specific idiotype
immunoglobulin has been reported to expand Treg cells in
vitro [48], although the specific epitope(s) or immunoglob-
ulin domain(s) that are immunosuppressive in MM patients
remain to be identified. Both Treg cells and myeloid-
derived suppressor cells (MDSCs) were detected at increased
frequency in a cohort of 76 patients with MM [46]. Treg
cells were expanded only in patients at diagnosis, but not in
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Figure 1: Interactions between myeloma and microenvironmental cell types. It is widely accepted that the BMmicroenvironment promotes
myeloma growth [23]. Several cytokines can be released upon the interaction of MM plasma cells and BM microenvironmental cells,
such as BM stromal cells (BMSCs), BM endothelial cells (BMECs), and osteoblasts. Among them, HGF is an attractive target for therapy,
given its undisputed role in disease pathogenesis and its potential contribution to the myeloma-induced immune dysfunction through the
upregulation of (IDO1) in MM cells. Insulin-like growth factor- (IGF-)1 receptor is also aberrantly expressed by myeloma cells and it has
been associated with a poor prognosis [24]. The activation of cytokine networks ultimately leads to the development of immune suppression,
through eﬀects on Treg cells andDC. For instance, HGF has been shown to inhibit DC function both inmice and in humans [25, 26], favoring
the emergence of tolerogenic DC. The main signaling pathways activated by HGF, IL-6, and other cytokines implicated in MM pathogenesis
are indicated.
those in remission or in patients with MGUS. The Treg cells
were capable of inhibiting the proliferation of autologous
responder CD4+ and CD8+ T cells by only 10% and 25%,
respectively, suggesting that they may be dysfunctional.
Another study conducted in 128 MM patients and 44 MGUS
patients showed an increase of Treg cells, especially in the PB
compared with the BM compartment [47]. The Treg cells
from MM patients mediated similar levels of suppression
of autologous T-cells compared with Treg cells from age-
matched controls. Although Treg-cell numbers positively
correlated with the paraprotein level, the highest numbers of
Treg cells were identified in patients with low disease burden
at the end of treatment in plateau phase response. In the
newly diagnosed MM patients, there was a trend toward
increased Treg numbers in the ISS stage II versus stage I.
Finally, Treg numbers did not correlate with PB or BM levels
of either IL-10 or TGF-β.
Another study involving 67 MM patients has shown that
in both MGUS patients and untreated MM, as well as treated
MM patients, the frequency of FoxP3-expressing T cells is
increased compared with healthy controls [45]. Treg cells
were isolated from 7 patients with untreated MM and were
cocultured with allogeneic CD4+CD25− T cells stimulated
with irradiated PBMC as stimulators. On a percell basis,
Treg from MM patients were equally eﬀective at inhibiting
allogeneic T-cell proliferation when compared with Treg cells
from healthy controls. The inhibition of proliferation of
conventional T cells by Treg cells from MM patients roughly
equaled 60% when allogeneic T cells and Treg cells were
cocultured at a (1 : 1) ratio. The same levels of suppression
were observed when Treg cells from patients with MGUS
were used in the coculture experiments.
Further analyses in 2 patients with MM suggested that
Treg cells were mainly derived through the peripheral expan-
sion of Treg cells, rather than through Treg generation within
the thymus. Another study has shown that the frequency of
FoxP3-expressing PBMC may be reduced in patients with
MM or MGUS compared with healthy controls [49]. When
cocultured with anti-CD3-activated PBMC, patient-derived
Treg cells failed to suppress T-cell proliferation, even when
added at a 10-fold higher number. It has been shown that the
combined assessment of CD127 and FoxP3 expression may
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be superior to CD25/FoxP3 for an accurate identification
of Treg cells in patients with cancer, including MM [50].
Collectively, these ex vivo studies suggest that Treg cells
are abnormal in MM, either quantitatively or qualitatively.
However, the biologic basis for Treg dysfunction in patients
with MM and MGUS remains to be fully elucidated.
Importantly, Treg cells vigorously expand in the BM
of MM patients given allogeneic HSCT [51]. At a median
of 37 months from transplantation, BM-residing CD4+ T
cells were markedly reduced compared with newly diagnosed
MM patients and with healthy controls. Conversely, Treg
cells were strongly enriched within the BM of transplanted
patients, expressed TGF-β and CTLA-4, and exhibited full
suppressor function against autologous non-Treg cells. The
low number of T-cell excision circles (TRECs) documented
in BM-resident Treg cells suggested that Treg cells were
derived extrathymically, as a result of peripheral expansion.
Finally, Treg cells preferentially expressed surface markers of
naı¨ve T cells, such as CD45RA. This study indicates that Treg-
cell expansion after allogeneic HSCTmay aﬀect antimyeloma
immunity and should be taken into consideration when
designing adoptive immunotherapy approaches.
It should be emphasized that pharmacological agents
active in MM, such as lenalidomide, thalidomide, and dex-
amethasone, may aﬀect Treg numbers. Lenalidomide treat-
ment in 8 patients with relapsed MM following allogeneic
HSCT was associated with an increase of Treg numbers [52].
Conversely, lenalidomide may reduce the percentage of Treg
cells in patients with chronic lymphocytic leukemia (CLL)
[53, 54] and with solid tumors or myelodysplastic syndromes
[55]. In vitro, lenalidomide inhibited Treg proliferation and
diminished FoxP3 expression in the absence of measurable
eﬀects on TGF-β or IL-10 production, while reducing Treg
cell accumulation in lymph nodes of CT26 cancer-bearing
animals [56]. It thus remains to be determined whether
lenalidomidemay overcome the barriers tomyeloma-specific
immunity through the modulation of Treg cells also in
humans. Similar to lenalidomide, thalidomide may diminish
Treg numbers in patients with CLL [57], whereas it does not
aﬀect Treg function in vitro [56]. Further studies are needed
to determine whether immune modulating drugs such as
thalidomide and lenalidomide may aﬀect Treg number and
function in patients with MM, leading to a better immune
control of the underlying disease.
5. BM Microenvironment and Immune
Dysfunction in MM
The BM microenvironment encompasses a wide spectrum
of cell types and extracellular matrix proteins, including
fibronectin, collagen, laminin, and osteopontin [23]. Among
the cell components, BMSC and bone marrow endothelial
cells (BMECs) physically interact with MM cells and con-
tribute to MM disease pathophysiology (Figure 1). BMSC
further enhance the myeloma-induced immune dysfunction,
by secreting factors such as VEGF, HGF, fibroblast growth
factor (FGF), and stromal-cell-derived factor (SDF)-1α. The
signalling pathways activated by the interaction between
accessory cells and MM cells lead to growth, survival, and
drug resistance of the latter, as well as to osteoclastogenesis
and angiogenesis. For instance, the adhesion of MM cells
to BMSC triggers the NF-κB-dependent secretion of IL-6
in BMSC, further stimulating MM cell growth, survival and
migration [58]. MM cells themselves secrete cytokines, such
as TGF-β and VEGF, which promote IL-6 release from BMSC
[59].
MM cells aberrantly express proangiogenic genes [60].
Although MM cells were shown not to express a significantly
higher number of pro- or antiangiogenic genes compared
with normal plasma cells, 97% of myeloma samples express
at least one angiogenic factor among the 6 most frequently
expressed factors, including HGF [61]. HGF is a 90-kd pro-
tein that signals through the MET receptor. Some MM cell
lines and primary myeloma cells also secrete HGF, suggesting
the occurrence of paracrine/autocrine interactions between
microenvironmental cell types and myeloma cells in vivo.
Stimulation of MM cells with HGF has been correlated
with the activation of signalling pathways implicated in
the regulation of cell proliferation and survival. Specifically,
MEK is required for HGF-induced proliferation, whereas
PI3K mediates myeloma cell rescue from apoptosis [62].
For biologic function, proteolytic conversion of single-chain
HGF to the heterodimeric active form is essential. HGF
activator (HGFA) is a factor XIIa-related serine protease
secreted by the liver and that potently activates HGF.
Intriguingly, HGFA levels are increased both in the PB and
BM of patients with MM, providing a prerequisite for HGF
activation in vivo [63]. Interestingly, myeloma cells catalyze
HGF activation by secreting HGFA [64]. The processing of
single-chain HGF was significantly enhanced by the addition
of thrombin and was completely inhibited by serine protease
inhibitors, such as aprotinin. Interestingly, single nucleotide
polymorphisms of the HGF gene have been associated with
myeloma risk [65].
High levels of HGF in serum and BM fluid of patients
with MM predict a dismal prognosis, with a survival time
of 32 and 21 months for patients with low and high HGF,
respectively [66]. HGF values have been reported to decline
after treatment with high-dose chemotherapy in patients
with MM who obtain at least a partial response. Clinical
responses to bortezomib and to high-dose chemotherapy
have been shown to correlate with low pre-treatment con-
centrations of HGF [67, 68]. Conversely, pretreatment levels
of other proangiogenic cytokines, such as VEGF and FGF,
were not significantly diﬀerent in responders versus non-
responders. The Nordic Myeloma Study Group has shown
that HGF is elevated in 25% of patients at diagnosis [69].
Following high-dose chemotherapy, median survival was not
reached after 77 months in patients with normal HGF values,
whereas in the group with elevatedHGF,median survival was
63 months. Furthermore, HGF declined in a high proportion
of MM patients at the time of disease remission.
Previously unappreciated eﬀects of HGF on the immune
response have been recently ascertained. In mice, treatment
with HGF in vitro and in vivo suppresses the antigen-
presenting function of DC [25]. The production of IL-12p70
is significantly inhibited by in vivo treatment with HGF,
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whereas IL-10 levels remain unaﬀected. HGF also inhibited
antigen-induced T-cell activation in an indirect manner.
Other studies showed that treatment with HGF amelio-
rates acute GVHD through eﬀects on the proinflamma-
tory cytokine cascades [70]. Serum IL-12 was significantly
decreased in HGF-treated mice with GVHD and both IFN-γ
and TNF-α were suppressed in target organs of GVHD,
translating into a higher survival rate.
Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-
catabolizing enzyme and is constitutively expressed by a
variety of human cancers, including acute myeloid leukemia
[71, 72]. IDO1 expression in tumor cell lines and primary
tumor cells is mainly triggered by IFN-γ and translates
into tryptophan degradation into immune suppressive
metabolites, collectively referred to as kynurenines [73].
We showed that HGF induces the expression of IDO1 in
human-monocyte-derived DC [26] and that IDO1 may be
expressed and functional in patients with MM, leading to
Treg expansion [35]. Serum kynurenines correlated with
HGF release, suggesting that HGF targeting should translate
into restoration of antimyeloma immunity.
6. DC Dysfunction in MM
In mice, myeloma cells or tumor culture-conditioning
medium (TCCM) inhibit the diﬀerentiation and function of
DC, as shown by the lower expression of DC-related antigens
and compromised capacity to activate allospecific T cells
[74]. Treatment with TCCM activated p38mitogen-activated
protein kinase (MAPK) and Janus kinase (JNK) but inhibited
extracellular regulated kinase (ERK). The inhibition of p38
MAPK restored the phenotype, cytokine secretion, and
function of TCCM-treated DC, pointing to these alterations
as novel mechanisms for tumor evasion that can be targeted
to obtain more potent DC vaccines.
The absolute number of circulating precursors of
myeloid and plasmacytoid DC may be significantly lower
in MM patients than in healthy subjects [38]. In addition,
patient-derived DC express significantly lower amounts of
HLA-DR, CD40, and CD80 and are impaired in their ability
to induce allogeneic T-cell proliferation. These phenotypic
features closely resemble those assigned to tolerogenic DC
populations [75]. The upregulation of CD80 on DC derived
from MM patients is defective during stable disease and
absent during progressive stages [38]. The inhibition of
CD80 upregulation was reverted by blocking antibodies
against TGF-β or IL-10. Although TGF-β and IL-10 are nor-
mal in most MM patients, cytoplasmic TGF-β was increased
in plasma cells during progressive disease. Brown et al. [76]
have further shown that DC numbers are only significantly
decreased in patients with stage 3 disease. Both IL-12 and
IFN-γ neutralize the failure to stimulate CD80 upregulation
in vitro, suggesting that the addition of these cytokines to
future immunotherapy trials should be considered. When
investigating the eﬀects of IL-6 on DC development and
function, Ratta et al. [77] have demonstrated that IL-
6 inhibits the colony growth of CD34+ DC progenitors
and switches the commitment of CD34+ cells from DC
to CD1a−CD14+ monocytic cells with potent phagocytic
activity but without antigen-presenting function.
Inflammatory cytokines reportedly induce immunogenic
DC suitable for immunotherapy. It has also been shown that
human, monocyte-derived DCs matured in the presence of
IL-1β, IL-6, and TNF-α expand functional Treg cells from
patients with MM [78]. Importantly, the numbers of Treg
cells may increase after the injection of cytokine-matured
DC, as shown in 3 patients with MM and 1 patient with
advanced renal cell cancer. The DC-mediated expansion
of Treg cells was rapid, occurring as early as 7 days after
the first DC injection, but was not associated with clinical
deterioration or decline in virus-specific immune responses.
This study underscores a potentially detrimental role of
vaccine-mediated induction of FoxP3+ Treg cells in patients
with MM, a previously unappreciated eﬀect in trials of
human DC vaccination, and supports the need to combine
DC therapy with approaches that selectively ablate Treg cells
or inhibit their function.
7. Novel Strategies to Target Immune
Suppressive Circuits in MM
CT-011 is a novel IgG1 humanized antibody that modulates
the immune response through interaction with PD-1. MM
cells express cognate ligands for PD-1, such as PD-L1. A
phase I clinical trial of patients with advanced malignancies,
including MM, has shown that CT-011 administration as
a single intravenous dose is safe and well tolerated, with
expansion of T-cell subsets and evidence of response in 33%
of patients [79] (Table 1). CT-011 increases the migration of
natural killer (NK) cells toward MM targets and enhances
immune synapses between patient-derived NK cells and PD-
L1-bearing, primary autologous MM cells [80]. CT-011 also
increased NK-cell IFN-γ secretion against primary MM cells
and enhanced NK cytotoxicity. Interestingly, lenalidomide
downregulated PD-L1 expression on CD38+CD138+ pri-
mary MM tumor cells, independent of a direct apoptotic
eﬀect, suggesting that dual immunotherapy with CT-011
and lenalidomide may be justified in patients with MM.
PD-L1 blockade has also been combined with syngeneic
HSCT- and DC-based vaccination to improve outcomes in
myeloma-bearing mice [81]. The PD-L1-expressing 5T33
tumor cell line was used to induce myeloma in mice.
Interestingly, inhibition of the PD-1/PD-L1 pathway com-
bined with HSCT and whole-cell vaccination increased the
survival of myeloma-bearing mice from 0% to 40%. These
results suggest that expression of PD-L1 can serve as a
potent mechanism for potentially immunogenic tumors to
escape from host immune responses, and that blockade of
interaction between PD-1 and PD-L1 may oﬀer a promising
strategy for specific tumor immunotherapy.
It has been demonstrated that theMM immune tolerance
can be overcome by modifying DC to express CNX, an acces-
sory protein that enhances antigen processing and promotes
DC and T-cell interactions [48]. CNX plays a key role in
both major histocompatibility complex-class 1 and 2 antigen
processing pathways and may also be involved in CD1d
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Table 1: Immune suppressive circuits and molecular targets for immunotherapeutic approaches in MM. The mechanisms of immune
evasion mediated by MM cells and the currently available strategies to target them are summarized.
Determinant(s) of
immune dysfunction
Eﬀect(s) on
antimyeloma immune
responses
Target(s) for
intervention
Immunotherapeutic
strategy
Phase of development
(either pre-clinical or
clinical)
Reference(s)
Secretion of
proangiogenic cytokines
within the MM
microenvironment
-Induction of
tolerogenic DC
-Induction of IDO1
Anti-HGF antibodies
Not yet into the clinic
for MM
[27, 28]
MET inhibitors
Not yet into the clinic
for MM
[29]
HGF
Anti-MET antibodies
Not yet into the clinic
for MM
[30]
NK4 (HGF antagonist) Not yet into the clinic [31, 32]
VEGF Bevacizumab Phase II, randomized [33]
Expansion of
CD25+Foxp3+ Treg cells
Inhibition of
antimyeloma immunity
CD25
-Denileukin Diftitox
(ONTAK)
-CTLA4-Ig
Not yet into the clinic
for MM
[34]
Enhanced tryptophan
catabolism
Inhibition of
antimyeloma immunity
IDO1 IDO1 chemical inhibitors
Not yet into the clinic
for MM
[35, 36]
Expression of
co-inhibitory receptors
and other immune
suppressive molecules
Expansion of Treg cells
and inhibition of
antimyeloma immunity
PD-L1
Anti-PD-1 antibodies
(CT-011)
Pre-clinical [15, 16]
TGF-β Anti-TGF-β antibodies Not yet into the clinic [37]
IL-10 Anti-IL-10 antibodies Not yet into the clinic [38]
DC dysfunction
Inhibition of
antimyeloma immunity
-MUC1
-Other MM
antigens
DC/myeloma fusion cells Phase I [39]
Weak immunogenicity
of MM-associated Id
proteins
Weak antimyeloma
immunity
Patients’ idiotype
Id-based and DC-based
vaccines
Phase I/II [40–42]
Maintenance of
clonogenic MM
precursors
Unrestrained growth of
MM cells
SOX2
Generation of
SOX2-specific T cells with
peptides spanning the
SOX-2 protein
Not yet into the clinic [21]
lipid antigen presentation [82]. Lentivirus-CNX-modified,
myelomaDC eﬀectively boosted cytokine production in both
CD4+ and CD8+ T cells and increased cancer cell killing.
These findings indicate that the tolerogenic DC in MM
patients may be engineered into reactive DC to promote
anticancer immunity with potential clinical benefit.
As discussed above, HGF is largely implicated in MM
pathogenesis and is an intriguing target for antiangiogenesis
and immunotherapy approaches (Table 1). MET-dependent
invasive growth signals are currently viewed as a general
feature of highly aggressive tumors. Molecules that inhibit
MET and HGF can thus interfere with cancer onset and
metastasis [29]. NK4, an antagonist for HGF, is composed of
the NH2-terminal hairpin domain and 4 subsequent kringle
domains of the α-subunit of HGF and is structurally similar
to angiostatin. NK4 may exert antiangiogenic and tumor-
suppressing activities independently of HGF antagonism.
The expression of NK4 mediated by an adenovirus vector
has been induced in mouse tumor cell lines [31]. The
combination of NK4 with DC vaccination elicited synergistic
antitumor eﬀects. Tumor regression induced by NK4 andDC
therapy required mainly MHC class I antigen presentation
and T cells of the treated hosts [31]. Tumors in MHC class
I-deficient mice lacking CD8+ T cells grew progressively,
whereas MHC class 2-deficient mice responded to NK4
and DC vaccination with significant tumor suppression.
Importantly, HGF antagonism translated into the emergence
of antigen-specific CTL, as shown by the strong cytotoxic
responses against parental B16-F10 melanoma cells and
E.G7-OVA lymphoma cells achieved using splenocytes from
tumor-bearing mice treated with NK4 and DC [31]. Inter-
estingly, NK4 protein may stabilize the growth of MM cell
lines and control the activation of MET, ERK1/2, STAT3,
and AKT-1 [32]. When injected into myeloma-bearing mice,
recombinant adenovirus containing NK4 cDNA inhibited
myeloma growth, induced myeloma cell apoptosis, and
restrained angiogenesis [32]. Although the eﬀects of NK4
on antimyeloma immunity were not investigated, this study
clearly indicates that molecular targeting of HGF by NK4
may prove beneficial in MM. Amgen has recently reported
the generation of fully humanmonoclonal antibodies against
HGF that exhibit therapeutic potential in mice bearing
subcutaneous xenografts of human glioma cell lines with an
HGF-dependent autocrine loop [27, 83, 84]. In particular,
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AMG102 (rilotumumab; Amgen) is a fully human neutral-
izing mAb against HGF and is currently under evaluation in
patients with advanced solid tumors, both as monotherapy
and in combination with other agents [83, 84]. The systemic
administration of L2G7, another anti-HGF antibody from
Galaxy Biotech, translated into the induction of regressions
of glioma xenografts [28]. In vivo inhibition of glioblastoma
growth also occurred with 5D5, a one-armed antibody
against MET [30].
Finally, IDO1 inhibitors such as 1-methyl-tryptophan
(1MT) have entered the clinical arena and have shown
tolerability and induction of autoimmune responses in
patients with solid tumors [36].
IDO1 may be located downstream of cyclooxygenase-2
(COX-2), as shown by the downregulation of IDO1 activity
by COX-2 inhibitors [85, 86]. It has been shown that COX-2
expression by malignant PC confers an unfavorable progno-
sis to MM, being found in roughly 30% of newly diagnosed
and 50% of relapsed/refractory MM cases [87]. In experi-
mental pancreatic adenocarcinoma, the combined treatment
with mucin-1- (MUC1-)based vaccine and celecoxib, a
COX-2 inhibitor, elicited vigorous antitumor responses [88].
Mechanistically, the increased immune responses were cor-
related with the downregulation of circulating prostaglandin
E2 and IDO enzymatic activities, leading to decreased levels
of Treg cells within the tumor. This study strongly points to
the COX-2/IDO1 interplay as a potential target for treatment
also in MM.
7.1. Gene Modified T Cells. Human MM samples express
ligands for NKG2D. Human T cells engineered to express
chimeric NKG2D receptors consisting of NKG2D fused to
the CD3ζ cytoplasmic domain lyse human myeloma cells
[89]. The in vivo therapeutic eﬃcacy of the chimeric T cells
has been tested against an established 5T33 mouse model
of myeloma. Mice given chimeric T cells 5 and 12 days
after myeloma inoculation experienced longterm survival
compared withmice receiving wild-type NKG2DT cells [90].
The chimeric T cells could be found both in the spleen and
in the BM of myeloma-bearing mice, although they did not
survive long-term, being no longer detected 7 days after T-
cell injection. Interestingly, treatment with the chimeric T
cells increased the activation of the host immune system, as
reflected by the higher IFN-γ levels and CD69 expression
in T-cell-treated, MM-bearing mice [90]. A chimeric T-cell
receptor recognizing the carbohydrate antigen Lewis Y and
containing CD3ζ and the CD28 coreceptor has been recently
constructed [91]. Approximately 50% of primary myeloma
samples expressed the Lewis Y antigen, which was not
apparently related to any patient and clinical characteristics
[91]. The transduced anti-Lewis T cells secreted IFN-γ in
response to a myeloma cell line and specifically lysed Lewis+
myeloma targets. In addition, myeloma-bearing NOD/SCID
mice received four intravenous injections of either chimeric
T cells on days 0 (tumor challenge) and 1, 2, and 5, which
translated into a significant improvement of survival com-
pared with mice adoptively transferred with nontransduced
T cells [91].
7.2. DC- and Id-Based Tumor Vaccines. DC-bases vaccina-
tion strategies have been explored to stimulate antimyeloma
immune responses. The ex vivo generation of functionally
active DC populations for adoptive transfer may circumvent
the quantitative and qualitative disturbances of DC function
in cancer patients. Tumor cells have been fused with
autologous DC using polyethylene glycol, thus allowing the
presentation of a broad array of antigens in the context of
potent DC fusion partners. Bone-marrow-derived MM cells
and patient-derived DC were used to generate DC/tumor
fusions for a phase I clinical trial in 18 patients with
active MM who had received at least 4 prior chemotherapy
regimens [39]. The DC/tumor fusion cells were further
activated with GM-CSF in culture prior to adoptive transfer.
In 17 out of 18 patients, adequate numbers of DC/tumor
fusions were obtained. In 11 out of 15 evaluable patients,
vaccination elicited a 2-fold increase of CD4+ and CD8+ T
cells reactive against a tumor lysate [39]. Humoral responses
to vaccination also occurred, as suggested by the detection
of antibodies against regulators of G-protein signaling 19
(RGS19), heat shock protein 90 (HSP90), and BRCA1-
associated protein (BRAP). Myeloma disease was stabilized
in 11 of the 16 evaluable patients for a variable period of time
ranging from 2.5 (4 patients) to 41 months (1 patient) from
vaccination [39].
DC vaccination has been pursued in patients who
received an autologous HSCT, using the idiotype (Id)
determinants on theMM immunoglobulin as tumor-specific
antigens. Twenty-six patients with MM were enrolled in
a phase I study of DC-based vaccination after autologous
HSCT [92]. DCs were pulsed with the patient-derived Id
chemically coupled with keyhole limpet hemocyanin (KLH).
Of the 26 patients, 17 were alive with a median follow-
up of 34 months from transplantation. Anti-Id immune
responses were documented in 4 patients, 3 of whom were
in complete remission at the time of vaccination. The results
of a phase II trial of Id-loaded APC, APC8020 (Mylovenge),
given after autologous HSCTs for MM have been recently
reported. Twenty-seven patients were enrolled on this trial
and the outcomes were compared to that of 124 consecutive
MM patients transplanted during the same period at Mayo
Clinic [93]. After transplantation, 96% of patients in the
vaccine trial and 88% of database patients achieved an
objective response. Importantly, vaccinated patients had
a significantly better overall survival (median: 5.3 years)
compared with database patients (median: 3.4 years) [93].
The intranodal injection of Id-pulsed, CD40 ligand-matured
DC has also been pursued in 9 patients with smoldering
or stable myeloma disease [40]. Patients received low-dose
IL-2 subcutaneously. At 5 years after vaccination, 5 patients
had stable disease, whereas 4 patients had progressive
disease. No modifications of either circulating T and B
cells or BM plasma cells were observed compared with pre-
treatment levels. In another study, immunization with the
autologous myeloma Id-induced reductions of circulating
clonal tumor B cells in patients with early-stage disease [41].
Id vaccination has also been applied to patients receiving
high-dose chemotherapy followed by HSCT. Id vaccines and
immune adjuvants were administered, together with either
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subcutaneous IL-2 or GM-CSF, to MM patients who were
in disease remission at time of vaccination [94]. Delayed-
type hypersensitivity (DTH) could be detected in 8 out of
10 patients, whereas Id-specific T-cell proliferative responses
emerged in 2 out of 10 treated patients. Freedom from
disease progression ranged from 9 to 36 months. Id-based
DC vaccines were also given to MM patients 3 to 6 months
after autologous HSCT [42]. Each patient in clinical stage
III and with chemotherapy-responsive disease received 2 Id-
pulsed DC vaccines, separated by 4 weeks. In 2 patients,
Id-specific T-cell responses could be measured. With a
minimum followup of 16 months from autologous HSCT
and 3 months from DC-based vaccinations, 9 patients were
alive [42]. In a subsequent phase I trial from the same
authors, DC were obtained under serum-free conditions
and were pulsed with patient-derived Id determinants [95].
Eight of 10 patients who received the scheduled vaccinations
progressed, and 2 patients who were in partial response
before vaccination remained in a clinically stable condition,
with a followup of 25 and 20 months, respectively [95].
Id vaccines were combined with IL-12 or IL-12/GM-CSF
administration in order to augment immune responses and
improve clinical outcome [96]. In 1 out of 28 patients, a
partial clinical response could be observed, whereas 11 out of
28 patients mounted T-cell proliferative responses to the Id,
peaking within 8 weeks from the start of Id vaccination [96].
Collectively, DC- and Id-based immunotherapy trials have
led to the emergence of antigen-specific immune responses
in patients with MM, although clinical responses were
detected in a minority of patients, underscoring the need
for complementary strategies that overcome the myeloma-
induced downregulation of immune responses.
Ipilimumab is a CTLA-4 antagonistic antibody. CTLA-4
is a T-cell-specific molecule that outcompetes CD28 and
inhibits T-cell activation. In a phase III randomized, con-
trolled trial in 676 patients with metastatic melanoma, treat-
ment with ipilimumab improved the median overall survival
by 3.7 months [97, 98]. It is tempting to speculate that
CTLA-4 blockademay also restore immune responses against
myeloma, either alone or in combination with vaccination
strategy, as recently shown in patients with melanoma [99].
8. Concluding Remarks
MM has a unique ability to escape from immunosurveil-
lance. The molecular determinants of immune suppression
in MM can represent an ideal target to improve clini-
cal outcome. The BM microenvironment is increasingly
viewed as a crucial compartment where interactions between
myeloma cells and stromal cells occur, leading to excessive
plasma cell proliferation, survival, drug resistance, and
migration capacity. Given the complexity of myeloma cell-
microenvironmental interactions, combination therapies
will be required to increase cytotoxicity and improve drug
resistance [23]. The eﬀects of novel immunomodulatory
drugs on antimyeloma immunity remain to be thoroughly
addressed. For instance, bortezomib has been reported to
induce apoptosis in human monocyte-derived DC, but not
in T cells or B cells [100]. Bortezomib may also impair the
maturation of 6-sulfo LacNAc DC, a major subset of human
blood DC, thus limiting the release of TNF-α and IL-12
[101]. It is presently unknown whether the down-regulation
of DC function induced by bortezomib may adversely aﬀect
in vivo anti-myeloma immunity. A better understanding of
the mechanisms underlying immune escape by myeloma
cells will set the stage for clinical trials aimed at overcoming
the immune system dysfunction associated with MM.
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